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Introduction: The use of hormonal implants has gained positive traction in family planning 
programs in recent times. Compared to other popular methods, such as long-term reversible 
intrauterine devices, the use of hormonal implants as a family planning method has distinct 
advantages in terms of long-term efficiency and better user compliance and availability. This 
paper presents a study protocol to document and evaluate the efficacy, safety, and acceptability 
of Femplant (contraceptive implant) in Pakistan during the first year of its use among married 
women of reproductive age (18–44 years) at clinics in two provinces of Pakistan (Sindh and 
Punjab).
Materials and methods: A total of 724 married women were enrolled in a noncomparative 
prospective observational study. The study involved six government clinics from the Population 
Welfare Department in Sindh Province and 13 clinics run by the Marie Stopes Society (a local 
nongovernmental organization) in both provinces. The participation of women was subject to 
voluntary acceptance and medical eligibility. All respondents were interviewed at baseline and 
subsequently at each scheduled visit during the study period. Side effects, complications and 
adverse events, if any, were recorded for every participant at each visit to the facility.
Discussion: Over the next 5-year period (2013–2018), 27 million hormonal implants will be 
made available in lower- to middle-income countries by international donors and agencies. 
The evidence generated from this study will identify factors affecting the acceptability and 
satisfaction of end users with Femplant (Sino-implant II). This will help to guide policies to 
enhance access to and the use of long-acting contraceptive implants in Pakistan and similar 
developing countries.
Keywords: safety, efficacy, acceptability, implant, Femplant, contraception, family planning, 
Pakistan
Introduction
Reversible long-term contraceptive methods (LTCMs), including intrauterine devices 
(IUDs) and implants, have a proven record of long-term effectiveness, convenience, 
and high user satisfaction.1,2 When compared with short-term methods, hormonal 
implants are more reliable, have better efficacy (.99%), are more cost-effective, and 
demonstrate high method-continuation rates (80% at 2 years postinsertion).3,4,5–9 Due 
to convenient use and better availability, implants are becoming increasingly popular 
when used in family planning programs.4
Hormonal implants are considered safe and suitable for nearly all women.10 They 
also offer great promise and  privacy in helping to meet the needs of younger women, 
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who often face social and cultural barriers to accessing effec-
tive modern contraception.11
The implants are made of thin, flexible, matchstick-sized 
rods of soft plastic.12 The rods contain progestin hormone, 
and are surgically placed beneath the skin of a client’s upper 
arm by a trained provider, who performs a minor surgical 
procedure under local anesthesia to insert or remove the 
rods. Implants can be removed whenever a woman wishes 
to have them removed, and thus they do not affect the return 
to fertility.6
Complications are uncommon, but may include infection 
(3%–7%) at insertion sites, difficulties in removal, and rarely 
expulsions. The use of hormonal implants is commonly 
followed by changes in bleeding patterns including lighter 
bleeding, fewer days of bleeding, irregular bleeding last-
ing more than 8 days, infrequent bleeding, and no monthly 
 bleeding. About 20%–30% of clients may experience few 
other minor side effects, such as headache, abdominal pain, 
acne, changes in weight, breast tenderness, dizziness, changes 
in mood, and nausea. However, these changes eventually 
diminish with time.13,14 Although the acceptability of bleeding 
disturbances varies in different cultures, studies have pointed 
out that efficacy and safety, factors related to simplicity, ease 
of use, acceptability, satisfaction, and contraceptive benefits 
can play a role in influencing the adoption of hormonal 
methods and determining consistency of use.5,15,16
context
Of the 208 million unintended pregnancies in 2008, nearly 
90% occurred in the developing world.17 In 2012 alone, more 
than 220 million women in the developing world had an 
unmet need for modern contraception, although this number 
had decreased from 226 million in 2008.18 However, the 
unmet need for modern contraception in 69 of the world’s 
poorest countries has seen an increase of 9 million (from 
153 to 162 million women) between 2008 and 2012, and 
thus accounts for 73% of all unmet need in the developing 
world.18
This high unmet need for contraception, as well as con-
traceptive failures in the developing world, was responsible 
for 80 million unintended pregnancies in 2012. Out of those, 
40 million ended in abortions, 30 million in unplanned 
births, and the remaining 10 million were terminated as 
 miscarriages.18 Access to contraception is low among 
women who are poor, less educated, rural, and young (aged 
15–24 years).18,19 Almost 99% of maternal deaths occur in 
 low-resource countries.20 The risk of maternal morbidity 
and mortality is higher among poorer women, who have less 
access to modern contraception, including implants.21 Among 
the women whose needs for contraception are met, many use 
less effective and supply-dependent methods. These include 
short-acting methods that require users continually to stock 
up their contraceptive supplies, as they do not have access 
to highly effective and more convenient long-term methods, 
such as implants.11
It is estimated that meeting the unmet need for contracep-
tion could reduce maternal mortality by 29% and prevent 
more than 100,000 maternal deaths each year globally.22 
Additionally, satisfying the unmet need for modern con-
traception in developing countries would further prevent 
54 million unintended pregnancies, including 21 million 
unplanned births, 26 million abortions (of which 16 million 
would be unsafe), and 7 million miscarriages; this would 
also help to prevent 1.1 million infant deaths.18
Globally, 56% of married women aged between 15 and 
49 years use a modern method of contraception. However, 
the worldwide implant-prevalence rate is extremely low, at 
0.3%. Interestingly, very few countries – including some of 
the very developed or developing countries – document the 
highest implant-use rate in the world, which ranges from 
1% to 6%.7 The reasons cited for the low use of implants, 
particularly in developing countries, include:
•	 for clients, the initial high cost of implants compared with 
other contraceptive methods;
•	 for service providers, lack of formal training on insertion 
and removal of implant.
The use of implants as an LTCM can be considered 
cost-effective provided the discontinuation rate remains low, 
one of the reasons for which is lack of formal training on 
insertion and removal.5 However, studies have shown that 
a huge number of women would choose implants or other 
long-term methods if these were available.16
Complications during pregnancy and childbirth remain 
the most frequent cause of death for women in Pakistan, as 
in other developing countries.23 Each year, around 12,000 
maternal deaths occur in Pakistan due to pregnancy-related 
complications.24,25 The risk of a woman dying as a result of 
pregnancy or childbirth during her lifetime is about one in 
4,700 in developed countries.26 In Pakistan, on the other hand, 
the risk is about one in 89.23 The high fertility rate of 4.1 
children per woman is highest among women who are poor, 
uneducated, and live in rural areas. Of every four pregnancies, 
one is unplanned. Modern contraceptive use has remained 
stagnant at around 30% for over a decade. At 25%, the unmet 
need for contraception remains unacceptably high, especially 
for women in the lowest income quintile (at 31%), women 
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with less education, and women in rural communities. Use 
of modern contraceptive methods among currently married 
women stands at 22%, and is further lower among women 
in rural areas – 17%. Short-term and permanent methods are 
the most common contraceptive methods used in Pakistan, 
while the use of long-acting and reversible methods like IUDs 
and implants is only 2.3% and 0.1%, respectively.23 If only 
4% of current oral contraceptive users (100,000 women) in 
Pakistan switched to IUDs or implants, it is estimated that 
more than 25,000 unintended pregnancies could be averted 
over a 5-year period.27
Some studies from developing countries have suggested 
that poor screening, insufficient counseling, and health 
concerns could be some of the reasons for the lower use 
of LTCMs.28,29 However, these studies mainly looked at 
determinants of contraceptive uptake, rather than reasons 
for continuation or discontinuation. Therefore, a lack of 
empirical evidence on LTCMs has been identified as one of 
the most important gaps in promoting and increasing their 
use in Pakistan.29
the contraceptive method: Femplant
The two-rod subdermal contraceptive implant Sino-implant 
(II) (Shanghai Dahua Pharmaceuticals, Shanghai, People’s 
Republic of China) is one of the most effective contraceptives 
available today.8 It was registered as Femplant in Pakistan in 
2010. Like Jadelle® (Bayer, Leverkusen, Germany), another 
implant system, the Chinese product contains 150 mg of 
levonorgestrel in two rods, and it has an annual pregnancy 
risk of lower than 1%. However, the per-unit wholesale cost 
of Femplant (approximately US$8) in the year 2010–2011 
was considerably lower than the current public sector price of 
Jadelle ($21), but in early 2013 Jadelle’s public sector price 
dropped to $8.50.31
Femplant is a set of two flexible, cylindrical rods made 
of milky-white, medical-grade silicone elastomer. Each rod 
contains 75 mg of levonorgestrel, the active ingredient. The 
rods are inserted into tubes composed of a colorless, trans-
parent form of silicone elastomer. Both ends of each tube 
are sealed with an adhesive. Levonorgestrel, a progestin, is a 
synthetic hormone. It mimics progesterone, a potent inhibi-
tor of sex hormones secreted by the pituitary gland. Like 
progesterone, levonorgestrel suppresses ovulation. It also 
thickens cervical mucus, which impedes the  migration of 
sperm. Femplant is indicated for women of childbearing age 
who wish to use an LTCM.
The two Femplant contraceptive rods are usually inserted 
during the first week of a woman’s menstrual cycle  (starting 
from the first day of menstruation), or at any other time 
when it is reasonably certain that the woman is not pregnant. 
A 0.2 cm-long incision is made in the skin of the upper 
arm or in the inside of the thigh, and the rods are implanted 
beneath the skin with a trocar (surgical instrument) under 
local anesthesia and aseptic conditions. An adhesive bandage 
is applied to cover the surface of the incision, and then the 
limb is wrapped with gauze.
Femplant provides effective contraception for at least 
4 years. Medical contraindications include current (history 
of) breast cancer; severe liver disease; acute deep venous 
thrombosis or pulmonary embolism; unexplained vaginal 
bleeding; lactation during the first 6 weeks postpartum; 
and systemic lupus erythematous with positive or unknown 
antiphospholipid antibodies.10
The adverse effects of Femplant are similar to other 
levonorgestrel-releasing implants (eg, Jadelle, Norplant). 
The vast majority of levonorgestrel-implant users experience 
menstrual problems, but serious bleeding problems are not 
more frequent than in controls. Other adverse events (AEs) 
may include skin conditions, headaches, dizziness, nervous-
ness, weight change, anxiety, and nonclinical depression. 
Most of these side effects are mild, and normally resolve 
spontaneously after several months of use. More serious AEs 
(ie, hypertension, gallbladder disease) are rare.29
For over 50 years, progesterone has been used in the 
treatment of recurrent endometrial cancer in the form of 
pills, injections, implants, and long-acting progestin IUDs, 
which are also known as the levonorgestrel intrauterine 
system (LNG-IUS). This LNG-IUS is used especially in 
breast cancer patients taking tamoxifen (TAM) to prevent 
endometrial proliferation. A recent systematic review, though, 
concluded that there was no significant relationship between 
breast cancer and the use of long-acting progestin-releasing 
devices, such as LNG-IUS, but still unclear about the pos-
sible effects of Mirena® (Bayer) or LNG-IUS on the breast. 
Therefore, the use of any long-acting progestin-only device, 
whether for an IUS/IUD or implant, requires both caution and 
more detailed clinical evidence for decision making, which 
right now is limited.30
rationale for the study
The contraceptive effectiveness and safety of Sino-implant 
(II) was evaluated in 15 clinical trials, all conducted in the 
People’s Republic of China.14 Outside these clinical trial set-
tings, more than 7  million units of Sino-implant (II) have 
been distributed, mainly in the People’s Republic of China 
and Indonesia. Although the documented clinical experience 
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with Sino-implant (II) outside these Asian countries is limited, 
preliminary data (during the first of year of use) from a study 
conducted in Madagascar in 2012 documented promising levels 
of safety, effectiveness, and acceptability of Sino-implant (II).31 
Therefore, the findings of this study will contribute to the body 
of knowledge on the clinical performance of Femplant outside 
the People’s Republic of China, Indonesia, and Madagascar.
Study partners
The Marie Stopes Society (MSS) is one of the leading 
 nongovernmental organizations in Pakistan, and has been 
providing a full range of high-quality family planning and 
reproductive health services to save and improve women’s lives. 
The MSS is part of the Marie Stopes International (MSI) global 
partnership, committed to and recognized for the highest clinical 
and operational standards. FHI 360, with support from the Bill 
and Melinda Gates Foundation, provided technical assistance 
to facilitate the introduction of Sino-implant (II) (registered by 
the MSS in Pakistan as  Femplant) – a low-cost, highly effective 
contraceptive implant – in resource-constrained countries. With 
funding from the US Agency for International Development, 
FHI 360 entered into a partnership with the MSS, and provided 
financial and technical assistance to implement the prospective 
cohort study with the aim of assessing Femplant safety, effec-
tiveness, and acceptability in Pakistan. Engender Health has also 
implemented a prospective cohort study in Bangladesh.
Study objective
This study aimed to evaluate the contraceptive effectiveness, 
safety, and acceptability of Femplant during the first year of 
its use in Pakistan. Specific objectives were to conduct the 
postapproval monitoring of:
•	 the contraceptive effectiveness of Femplant during the 
first year of use
•	 safety of Femplant during the first year of use
•	 side effects and complications during Femplant insertion 
or removal
•	 acceptability of Femplant during the first year of use
•	 women’s satisfaction with Femplant services.
Study design
This was a noncomparative prospective observational study 
of women using Femplant as a primary method of contracep-
tion in the two most populous provinces of Pakistan – Sindh 
and Punjab. The provinces were selected on the basis of high 
levels of population concentration, similar sociodemographic 
characteristics, and relatively better law-and-order situa-
tions compared with other provinces. Overall, the study was 
conducted in a total of 19 clinics, including six government 
clinics from the Population Welfare Department (PWD) 
in Sindh, and 13 clinics run by the MSS nongovernmental 
organization in both provinces. These clinics had sufficient 
expected client flow per month and were geographically 
(urban- or periurban-based) accessible, facilitating enroll-
ment and follow-up of women in the prospective study.
A total of 724 women, divided into two cohorts, were 
enrolled in this 1-year prospective study, comprising:
•	 a prospective cohort consisting of 392 women who were 
followed up at 3 and 12 months after enrolment
•	 a surveillance cohort of 332 women who returned to the 
clinic within 12 months after enrollment if they experi-
enced complications, medical problems, pregnancy, or 
wanted to remove the Femplant.
Originally 600 women were supposed to be enrolled but 
during the course of study enrollment, there were 124 over-
enrollments. This overenrollment was communicated to the 
Pakistani and FHI 360 institutional review boards (IRBs).
Prior to initiation of the study, we randomly desig-
nated clinics to enroll women into either the prospective 
or surveillance cohorts. Women were recruited into the 
study during their routine family planning visit at either 
the participating government-run or MSS clinic. During 
the initial visit after the woman had selected to use the 
Femplant as her contraceptive method, research staff intro-
duced and explained the study objectives and procedures 
and potential risks and benefits of participation. Women 
who agreed to participate in the study were asked to sign a 
consent form documenting their voluntary decision to join 
the study. After signing the informed consent form, each 
potential participant was evaluated for medical eligibility 
and admitted into the prospective or surveillance cohort, 
depending on which arm the clinic had been allocated to. 
Women in the prospective cohort were asked to return to 
the clinic both 3 and 12 months after the Femplant insertion 
to be interviewed and evaluated for pregnancy, AEs, and 
method acceptability. Women in both cohorts were encour-
aged to return to the clinic at any time if they experienced 
medical problems or other problems related to the implant, 
or became (or suspected that they might be) pregnant, or if 
they wanted to remove the implant.
Study population and inclusion criteria
Married women of reproductive age (MWRA) were quali-
fied to participate in the study. To be eligible for inclusion, 
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women had to be between 18 and 44 years of age, inclusive. 
They must have chosen to use Femplant for contraception, 
be medically eligible for this method of contraception, and 
give informed consent.
Sample size/sampling strategy
The sample estimation was based on the following 
assumption: if we enroll 300 women and assume that loss 
to follow-up at 12 months is less than 20% and the true 
12-month cumulative probability of pregnancy is no more 
than 1%, then we will have a 90% chance of both ruling 
out a 4.5% pregnancy probability (ie, obtaining an upper 
95% confidence bound of less than 4.5%) and obtaining 
an estimated 1-year pregnancy probability of less than 2%. 
Our assumptions of the first-year probability of pregnancy 
were based on data from the four randomized trials with a 
total of 15,943 women assigned to Sino-implant (II) that 
showed first-year probabilities of pregnancy ranging from 
0.0% to 0.1%.8
timeline
The overall duration of this study was about 26 months: from 
October 2010 to January 2013. The first 5 months comprised 
writing the study protocol, developing study instruments and 
securing ethical approval from the IRBs from FHI 360 and 
Pakistan. The field component consisted of recruitment, and 
follow-up took about 16 months. Data entry, analyses, and 
report writing were carried out in the final 4 months.
Study setup, visits, and procedures
Admission
Once enrolled in the study and after the implant was inserted 
(as described earlier), all women underwent the baseline 
interview. After the baseline interview, all MWRA in the 
prospective cohort were asked to return to the clinic both 3 
months and 12 months after the insertion to be interviewed for 
complications, AEs, and acceptability, and to be  evaluated for 
pregnancy. Women in both cohorts were asked to contact or 
return to the clinic if they experienced any medical problems 
or pregnancy while using the implant, or if they wanted to 
remove the implant.
Visits at 3rd and 12th month
During each follow-up visit, a research nurse conducted the 
follow-up interview and completed the appropriate case-
report form (CRF). A pregnancy test was administered at 
the month 3 visit, only if clinically indicated (eg, absence of 
menses for more than 6 weeks, other signs and symptoms of 
pregnancy, or woman’s concern that she may be pregnant), 
and in all women at the month 12 visit. Pregnant women 
were provided with counseling regarding their pregnancy 
options, implant removal, and prenatal care. If the woman 
wanted to or already had removed the Femplant, she was 
provided with family planning counseling as part of the 
standard of care. All efforts were made to contact women 
in person through phone calls on the numbers provided by 
them or approaching them through persons who had referred 
them to the study clinics.
unscheduled visits
During unscheduled visits, regular follow-up procedures 
were followed and study CRFs completed, if appropriate. 
Where personal contact was not possible, the follow-up 
interview was conducted via phone. All women were encour-
aged to seek medical care in the clinics where the implant 
was inserted or elsewhere if they experienced any medical 
problems or suspected that they may be pregnant after the 
study was over.
retention
Measures to improve retention
The study staff emphasized to each participant the impor-
tance of follow-up for the entire study period and the need 
to return for the follow-up visits. As mentioned earlier, 
participants were compensated for their transportation 
costs and time to attend the scheduled visits for an amount 
approved by the participating IRBs. Clinic staff collected 
contact information for each participant. If a participant 
missed a scheduled appointment, the clinic staff tried to 
locate her using all possible means (eg, telephone, mail 
contact, through referees, or possibly in person) and docu-
mented these attempts (at least three attempts were made). 
The study staff also collected contact information from each 
participant for a contact person who would know where 
the participant might be. With participants’ consent, these 
people were to be contacted in case the participant could 
not otherwise be found.
Study outcomes were:
•	 with the Femplant in place, the cumulative probability 
of pregnancy through 1 year
•	 prevalence and incidence rates of immediate and delayed 
complications associated with insertion or removal of the 
Femplant
•	 incidence rate of AEs related to use of the Femplant
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•	 cumulative probability of early discontinuation of the 
Femplant through 1 year
•	 reasons for discontinuation of Femplant
•	 level of women’s satisfaction with Femplant services.
Measurement of study outcomes
For 392 women enrolled in the prospective cohort, data 
related to satisfaction with MSS services, pregnancy, AEs, 
insertion complications, and acceptability information 
were collected through interviews and review of medical 
records during admission, follow-up at months 3 and 12, 
and during unscheduled visits. This information was docu-
mented on the corresponding CRFs. In addition, for another 
332 women enrolled in the surveillance cohort, data related 
to the main study outcomes were collected through an 
interview during unscheduled visits and documented on the 
corresponding CRFs.
Measurement of pregnancies
A rapid urine pregnancy test (available through the 
MSS in Pakistan) was performed during the month 3 or 
unscheduled visits, only if clinically indicated. At the 
month 12 visit, a pregnancy test was performed in all 392 
participants from the prospective cohort. The study staff 
ensured that information about all study pregnancies was 
documented on the follow-up and pregnancy-outcome 
forms accordingly. Whenever possible, date of conception 
was estimated based on the available information (date of 
last menses, etc). Pregnancies diagnosed elsewhere (ie, 
without confirmation in the study clinic) were considered 
study pregnancies.
Measurement of insertion/removal complications
The study staff reviewed the existing medical records for 
immediate insertion complications during the admission 
visit and documented it on the baseline form. All information 
related to delayed complications of the insertion procedure 
was collected during the month 3 or unscheduled visits, and 
documented on the follow-up form and serious AE (SAE) 
form, if appropriate. All complications related to removal 
(if occurring during the study) were documented on the 
 follow-up and SAE forms, if appropriate.
Measurement of adverse experiences
Research staff collected information on all SAEs and bleed-
ing problems that women reported during the month 3, 
month 12, or unscheduled visits (see the Safety section for 
more details on collecting safety data). The staff ensured that 
all safety information was documented on the follow-up and 
SAE forms, if appropriate.
Measurement of acceptability and continuation
Acceptability was evaluated based on continuation rates 
and reasons for discontinuation. It was also measured by 
responses to the acceptability questions during the follow-up 
interviews at the month 3, month 12, or unscheduled visits. 
In addition, information on acceptability and continuation 
was extracted from the existing records. The research staff 
made sure that all relevant acceptability information was 
documented on the follow-up form.
Measurement of women’s satisfaction  
with Femplant services
Information concerning women’s satisfaction with Femplant 
services was measured by responses provided during baseline 
interviews and during the admission visit, and documented 
on the baseline form.
completion of the study
A participant was considered to have completed the 
study:
•	 in the prospective cohort – after she had completed her 
month 12 follow-up visit, and after her final set of data 
had been collected and entered on the appropriate study 
CRFs
•	 in the surveillance cohort – after the 12-month follow-up 
of the prospective cohort had been completed and all data 
had been entered on the study CRFs
•	 in both cohorts – after she had become pregnant while 
using Femplant.
loss to follow-up
If a participant in the prospective cohort did not have 
any indication that the implant was removed and failed 
to appear for the scheduled 3- and/or 12-month visit, she 
was presumed lost to follow-up. Study files of participat-
ing MWRA who missed their appointments were kept 
open until study close in case they returned later for 
follow-up. If the participant did not return to the clinic 
before the study closed, the  follow-up form (namely, the 
final status question) was completed at the time of study 
close. The form would indicate that the participant was 
lost to follow-up; this designation was not made for any 
participant until the closing date of the study. “Lost to 
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follow-up” was not applicable to participants in the sur-
veillance cohort.
Study discontinuation
Participants were informed that they could withdraw from 
the study at any time, for any reason, without loss of other 
benefits or services to which they were entitled. We would 
discontinue participants from the study if any of the follow-
ing occurred:
•	 investigator or other physician decided that continued 
participation in the study would be harmful
•	 study was terminated, and/or other administrative 
reasons
•	 participant decided to or had already removed the 
implant
•	 participant decided to withdraw her participation in the 
study.
The study staff documented the reasons for early dis-
continuation of the Femplant on the follow-up form. Even 
when early discontinuation from the study occurred, the staff 
made reasonable efforts to collect and assess information 
relevant to the study outcomes at the time of discontinuation. 
We did not replace any discontinued or lost-to-follow-up 
participants.
Safety
Scope of safety data
An AE was any unfavorable and unintended sign, symptom, 
or disease temporally associated with the use of a study 
product, whether or not this was considered to be related to 
the product. Preexisting conditions were not considered AEs 
unless they increased in frequency or severity or changed 
in nature.
In this study, during both scheduled and unscheduled 
visits, we collected information on the following:
•	 SAEs
•	 immediate and delayed insertion complications
•	 immediate and delayed removal complications
•	 vaginal bleeding problems.
Operational definitions
An SAE was defined as any experience that suggested a sig-
nificant hazard, contraindication, side effect, or precaution. 
An SAE included any adverse experience resulting in any of 
the following outcomes:
•	 death
•	 a life-threatening adverse drug experience
•	 inpatient hospitalization (including overnight stay) or 
prolongation of existing hospitalization
•	 a persistent or significant disability/incapacity
•	 a congenital anomaly/birth.
All reported SAEs (other than insertion complications) 
were graded for severity as follows:
•	 mild (participant was aware of the AE all of the time, but 
was still able to do all activities)
•	 moderate (participant had to discontinue some activities 
due to the AE)
•	 severe (participant was incapacitated by the AE and 
unable to perform normal activities).
All reported SAEs were graded for relatedness to the 
Femplant as follows:
•	 unrelated (onset of the AE had no reasonable temporal 
relationship to administration of the study product, or 
causal relationship to administration of the study product 
was biologically implausible, or the event was attributed 
to an alternative etiology)
•	 possibly related (onset of the AE had a reasonable tem-
poral relationship to study-product administration, and 
a causal relationship was not biologically implausible)
•	 definitely related (onset of the AE showed a distinct 
temporal relationship to administration of the study 
product, or the AE was a known reaction to the product 
or chemical group or could be predicted by the product’s 
pharmacology).
All immediate and delayed insertion and removal com-
plications were graded for severity as follows:
•	 mild (did not require any medical intervention)
•	 moderate (only required resting or minimum level of 
medical intervention, such as taking pain medication)
•	 severe (required attention from medical personnel to 
conduct a medical intervention).
documentation and reporting of safety data
All SAEs in this study were documented on the follow-up 
and SAE forms and reported to FHI 360 using the SAE report 
form within 24 hours of the study site becoming aware of the 
problem, and if required to the local regulatory authorities 
and IRB, according to their policies. FHI 360 would report 
all SAEs in this study to FHI 360’s Protection of Human 
Participants Committee (PHSC), according to FHI 360’s 
standard operating procedures.
All insertion and removal complications, as well as  bleeding 
problems, were documented on the follow-up form. If any 
of these medical problems met the definition of an SAE, the 
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SAE form would have to be completed. For all SAEs related to 
bleeding problems or removal that occurred during the study, 
the standard SAE-reporting requirements were followed. Since 
the insertion was not part of this prospective study, SAEs related 
to the insertion would not be reported to FHI 360, but might 
be reported by the MSS to the regulatory authorities or local 
pharmacovigilance program in Pakistan as appropriate.
Pregnancy was a study outcome, and was not docu-
mented as an adverse experience. Information related to all 
study pregnancies was documented on the follow-up and 
pregnancy-outcome forms.
Social harm events
A social harm event was defined as an adverse social con-
sequence or outcome due to study participation. If the site 
principal investigator (PI) learned of a social harm event, 
he/she would report the event on the social harm event form 
to FHI 360 and the IRB within 3 days of becoming aware 
of the event.
data management
A detailed data-management plan was outlined prior to initia-
tion of the prospective study. The following is a brief summary 
of the plan. Study research assistants captured data obtained 
during the follow-up interview or transcribed the data extracted 
from the existing medical records on a two-ply paper CRF. The 
original copy was kept in the participant’s original file folder at 
the site for monitoring purposes, and the other copy was sent 
to the MSS local office for double data entry using EpiData 
version 3.1 (EpiData Association, Odense, Denmark).
The electronic datasets were available for interim and 
final review and analysis to the research staff at MSI and 
FHI 360. Details of data ownership and sharing between 
MSI and FHI 360 were specified in the final version of the 
data-management plan.
Monitoring plan
A study coordinator worked with the study nurse at each site 
and regularly monitored whether the study protocol, data-
collection process, and questionnaires were being properly 
followed. The following were monitored:
•	 any changes in the protocol that had been reported to 
the head of the Research, Monitoring and Evaluation 
 Department at the MSS and subsequently to the MSI 
project manager
•	 whether participants’ records were complete and 
accurate
•	 a log with participants’ names, addresses, clinic file 
numbers, and study participant numbers in a confidential 
location
•	 whether the study service-inventory log was current and 
showed the total number of procedures carried out
•	 whether any SAEs were being promptly documented and 
reported
•	 whether physicians and other study staff were carry-
ing out their activities as agreed upon prior to study 
initiation.
Analysis plan
A draft analysis plan was developed by FHI 360 and MSI 
prior to the initiation of the study. The following is a summary 
of the planned analysis. For the 392 women enrolled in the 
prospective cohort of this study, all information related to the 
study outcomes obtained through the follow-up interview was 
documented on the study CRFs. In addition, all information 
related to the main study outcomes for the other 332 women 
enrolled in the surveillance cohort was extracted from exist-
ing medical records or obtained during unscheduled contacts 
and visits, documented in the study CRFs, and included in 
the final analysis.
Descriptive statistics were used to analyze demo-
graphic and baseline characteristics. We used measures of 
central tendency and dispersion for continuous variables, 
including means, medians, standard deviation, and range. 
Categorical data were summarized with frequencies and 
percentages.
All SAEs reported during the study were supposed to be 
summarized in frequency tables (including both the number 
of each type of SAE and the number of distinct participants 
with each type of SAE); however, none had been reported 
at the completion of the study. Prevalence and incidence 
rates were calculated for immediate or delayed complica-
tions associated with insertion and/or removal. Rates of 
early discontinuations of the Femplant were computed, and 
reasons for discontinuation were summarized and presented 
in a tabular format. The 1-year cumulative probability of 
pregnancy and corresponding 95% confidence interval were 
computed using life-table methods, recording women at the 
time of implant removal or at the time of their last clinic visit, 
whichever came first. Women with no clinical indication of 
pregnancy (and hence no pregnancy test) were considered 
not to be pregnant through the time of their last clinic visit. 
Bleeding problems and rates were computed and presented 
in a tabular format.
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Potential risks and benefits
Potential benefits to participants
This study had no expected direct benefits to participants. 
However, the findings from this study should generate addi-
tional knowledge on the clinical performance of the Femplant 
and will benefit potential users of this method in the future. 
Participation in the study did not affect fees, payment, bill-
ing, or reimbursement for any other services at the clinic. 
Participants were, however, compensated for their time and 
trouble in completing the month 3 and month 12 visits in 
the amount of Rs250 per participant per visit (equivalent 
of ∼US$2.30).
Potential risks to participants
All possible efforts were made to prevent loss of confiden-
tiality during the study. Participation in this study had no 
other expected risks to participants. All women participating 
in this study had personally and voluntarily chosen to use 
the  Femplant for contraception before they were invited to 
participate in this prospective study. Study participants might 
have experienced certain side effects, including minimal 
risk of pregnancy, but these risks might have been due to 
use of the Femplant and not due to their participation in 
this study.
We had not anticipated any social harm events for par-
ticipants during the study, and no social harm event was 
reported during the course of the study. Despite that, we 
carefully monitored and intended to act accordingly if there 
was any unacceptable risk of social harm events resulting 
from participation in the study.
Ethical considerations
Institutional review boards
All investigators and research staff involved in the study had 
a commitment to respecting the ethical principles of clinical 
research. The study protocol, the informed consent form, and 
other appropriate documentation were reviewed and approved 
as required by the PHSC at FHI 360 (FWA00016827).
The study also received full clearance from the Ethics 
Review Committee of the National Bioethics Committee of 
the government of Pakistan, reference number 4-8711/NBC/-
65/RDC/386. The study is also archived at http://apps.who.
int/trialsearch/trial.aspx?trialid=NCT01463254.
Participating research staff were also trained in research 
ethics. The PI at the research site was responsible for 
 ensuring that all requirements of the local IRB were met. 
Before implementing any changes to the protocol, informed 
 consent, advertising, or written materials for participants, the 
site PI made sure that all of the changes were approved by 
FHI 360’s PHSC and the local IRB, except where necessary 
to eliminate immediate hazards to human participants. The 
PI was also responsible for notifying FHI 360 and MSI as 
soon as possible, after no more than 48 hours, if the local 
IRB withdrew its approval of this research at any time before 
its completion.
The site PI was also responsible for making progress 
reports to the local IRB and to FHI 360 and MSI annually 
and within 3 months of study termination or completion. 
These reports could include the total number of participants 
enrolled, the numbers and reason(s) for discontinuation, 
a description of all SAEs, the number of participants com-
pleting the study, all changes in the research activity, and all 
unanticipated problems involving risks to human participants 
or others. Copies of all study-related correspondence with 
the local IRB were also sent to FHI 360 and MSI.
Informed consent
The study staff explained the study and its associated pro-
cedures, risks, and benefits to the participants. The consent 
form was read verbatim to each participant. Each eligible 
participant was asked to sign the informed consent form 
if she wished to participate in the study. The consent form 
was written to be understandable for a 14-year-old (grade 8 
 reading level). The informed consent document was trans-
lated from English into the local Urdu language. It was made 
sure that each participant agreed to and understood the risks 
and benefits associated with her participation in this study, her 
rights to terminate participation in the study without affecting 
her health care at the site, whom to contact with questions 
regarding the study, and that she had freely given informed 
consent to participate in the study and to have her existing 
medical records related to the use of the Femplant reviewed 
and analyzed as part of the study. A friend/relative accom-
panying the woman or a clinic staff member not involved in 
implementing the study signed the informed consent form to 
confirm witnessing the agreement to participate in the study 
for all illiterate participants.
Due to the long-term nature of the implant and possible 
extension of the follow-up period of the study, all women 
were informed of the possibility of more annual follow-up 
contacts and asked for their permission to be contacted in 
the future. A copy of the signed informed consent form was 
also given to the consenting women. Therefore, the signed 
informed consent form became a permanent part of the 
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participant’s study records. It was stored separately from 
other participants’ records related to the study to protect their 
confidentiality.
Participants’ confidentiality
Except as required by law, all study staff were commit-
ted to protecting the confidentiality of participants to the 
fullest extent in order to protect their rights and welfare. 
 Participants’ contact information and informed consent 
documents with names were stored separately from the study 
CRFs. No participant’s personal identifiers appeared on any 
data or documentation sent to MSI or FHI 360. Participants 
were not identified by name in any report or publication 
resulting from the study data. Risk of loss of confidentiality 
might have occurred if these procedures were inadvertently 
breached. All possible efforts were made to prevent this 
from happening. The PI at the site permitted trial-related 
monitoring, audits, IRB review, and regulatory inspections 
by providing direct access to source data and other study-
related documentation.
report writing and dissemination plan
The FHI 360 and MSI research teams, working in close col-
laboration, will determine a detailed data-analysis  strategy and 
final report outlines, and describe it in the data- management 
and analysis plans prior to conclusion of the data collection. 
FHI 360 will perform analyses as specified in the analysis 
plan and draft a final report based on the data. A publication 
is planned following completion of the study.
Discussion
The research evidence from this study will help to identify 
factors affecting the acceptability of and users’ satisfaction 
with the Femplant (ie, Sino-implant [II]), and help to enhance 
access to and use of long-acting contraceptive implants in 
Pakistan and similar developing countries. The need for such 
research evidence has become more pertinent since interna-
tional donors, including Bayer and the World Health Organi-
zation, joined forces to make 27 million implants available in 
resource-constrained countries from 2013 to 2018.32 Further, 
there is a dearth of evidence available on the effectiveness 
and safety of this method outside the People’s Republic of 
China and Indonesia. Therefore, more specifically, the find-
ings of this study will contribute to the body of knowledge on 
clinical performance in Pakistan, which will provide timely 
recommendations for the successful introduction/marketing 
of this new LTCM in the country. Further, this new implant 
will fill the gap of need for a reliable and quality LTCM in 
the wake of PDHS findings of a fertility rate of 4.1 children 
per woman and only 0.1% of current implant use.23
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